Journal of Kerman University of Medical Sciences

Elevated Lipoprotein (a) and 10-Year Risk of Cardiovascular Disease among Iranian Patients with Bipolar Disorder

Document Type : Original Article

Authors

Shadi Naderyan feli 1
Seyed Mojtaba Yassini Ardekani 2
Maryam Askari 3
Ali Dehghani 4

1 MSc of Epidemiology, Department of Biostatistics and Epidemiology, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

2 Research Center of Addiction and Behavioral Sciences, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

3 Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

4 Department of Biostatistics and Epidemiology, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

https://doi.org/10.22062/jkmu.2021.91662
Abstract
Background:Bipolar disorder is associated with a high risk of cardiovascular disease. The aim of this study was to determine the elevated lipoprotein (a) level and 10-year risk of cardiovascular disease among patients with bipolar disorder.
Methods:This cross-sectional study was conducted on 100 patients with bipolar disorder in Yazd province, Iran. Elevated lipoprotein (a) concentration was defined as the lipoprotein (a) level of greater than 30 Mg/dL. The Framingham risk equation was used to estimate the 10-year risk of cardiovascular disease. The data were analyzed using Chi-square or Fisher's exact test, and independent sample-t or Mann-Whitney test. Statistical significance level was set at p ≤ 0.05.
Results:In this study, 75 male (75%) and 25 female (25%) patients with bipolar disorder were investigated. Based on the findings, smoking was significantly more prevalent among men than women (p <0.001). No statistically significant difference was observed between males and females with regard to the total cholesterol, high- and low-density lipoprotein cholesterol, systolic blood pressure, body mass index, and lipoprotein (a) (p>0.05). High levels of lipoprotein (a) were observed in 41% of the participants. Most individuals (77.3%) were at low risk for developing cardiovascular disease in the next 10 years.
Conclusion:The findings suggest a high level of lipoprotein (a) among patients with bipolar disorder. Most participants were at a low risk for developing cardiovascular disease in the next 10 years. Psychiatrists and health professionals should be informed about cardiovascular risk factors in bipolar patients and monitor them regularly for early detection.

Keywords

Lipoprotein (a)
Cardiovascular disease
Bipolar disorder
  1. Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large‐scale meta‐analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017;16(2):163-80.
  2. Tsai SY, Lee CH, Chen PH, Chung KH, Huang SH, Kuo CJ, et al. Risk factors for early cardiovascular mortality in patients with bipolar disorder. Psychiatry and clinical neurosciences. 2017;71(10):716-24.
  3. Gomes FA, Almeida KM, Magalhaes PV, Caetano SC, Kauer-Sant'Anna M, Lafer B, et al. Cardiovascular risk factors in outpatients with bipolar disorder: a report from the Brazilian Research Network in Bipolar Disorder. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). 2013;35(2):126-30.
  4. Motamed N, Mardanshahi A, Saravi BM, Siamian H, Maadi M, Zamani F. The 10-year Absolute Risk of Cardiovascular (CV) Events in Northern Iran: a Population Based Study. Materia socio-medica. 2015;27(3):158-62.
  5. Garcia-Portilla MP, Saiz PA, Bascaran MT, Martínez S, Benabarre A, Sierra P, et al. Cardiovascular risk in patients with bipolar disorder. Journal of Affective Disorders. 2009;115(3):302-8.
  6. Slomka JM, Piette JD, Post EP, Krein SL, Lai Z, Goodrich DE, et al. Mood disorder symptoms and elevated cardiovascular disease risk in patients with bipolar disorder. Journal of Affective Disorders. 2012;138(3):405-8.
  7. Costello BT, Silverman ER, Doukky R, Braun LT, Aggarwal NT, Deng Y, et al. Lipoprotein(a) and Increased Cardiovascular Risk in Women. Clinical cardiology. 2016;39(2):96-102.
  8. Peromingo JAD. Lipoprotein (a) and Cardiovascular Risk.  Recent Advances in Cardiovascular Risk Factors: InTech; 2012.
  9. Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Extreme lipoprotein (a) levels and improved cardiovascular risk prediction. Journal of the American College of Cardiology. 2013;61(11):1146-56.
  10. Emanuele E, Carlin MV, D'Angelo A, Peros E, Barale F, Geroldi D, et al. Elevated plasma levels of lipoprotein(a) in psychiatric patients: a possible contribution to increased vascular risk. European Psychiatry. 2006;21(2):129-33.
  11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical chemistry. 1972;18(6):499-502.
  12. Coke LA. Cardiac risk assessment of the older cardiovascular patient: the Framingham Global Risk Assessment Tools. Medsurg Nursing. 2010;19(4):253-4.
  13. Kouvari M, Panagiotakos DB, Chrysohoou C, Georgousopoulou EN, Yannakoulia M, Tousoulis D, et al. Lipoprotein (a) and 10-year Cardiovascular Disease Incidence in Apparently Healthy Individuals: A Sex-based Sensitivity Analysis from ATTICA Cohort Study. Angiology. 2019;70(9):819-29.
  14. Naderi GA, Sarraf-Zadegan N, Boshtam M, Asgari S, Afyooni A, Jalali A, et al. The situation of new risk factors of cardiovascular disease in urban population of Isfahan. Journal of Kerman University of Medical Sciences. 2004;10(1):28-35.
  15. Saeed A, Virani SS. Lipoprotein (a) and cardiovascular disease: current state and future directions for an enigmatic lipoprotein. Frontiers in bioscience (Landmark edition). 2018;23(January 1):1099-112.
  16. Scott G, Diane B, Luther C, Richard C, Margo D, James H, et al. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25).
  17. Silarova B, Giltay EJ, Van Reedt Dortland A, Van Rossum EF, Hoencamp E, Penninx BW, et al. Metabolic syndrome in patients with bipolar disorder: comparison with major depressive disorder and non-psychiatric controls. Journal of psychosomatic research. 2015;78(4):391-8.
  18. Moreira FP, Jansen K, Cardoso TA, Mondin TC, Magalhaes P, Kapczinski F, et al. Metabolic syndrome in subjects with bipolar disorder and major depressive disorder in a current depressive episode: Population-based study: Metabolic syndrome in current depressive episode. Journal of psychiatric research. 2017;92:119-23.
  19. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, et al. Lipoprotein (a) as a cardiovascular risk factor: current status. European heart journal. 2010;31(23):2844-53.
  20. Grover S, Nebhinani N, Chakrabarti S, Avasthi A, Basu D, Kulhara P, et al. Cardiovascular risk factors among bipolar disorder patients admitted to an inpatient unit of a tertiary care hospital in India. Asian Journal of Psychiatry. 2014;10(August 2014):51-5.
  21. Murray DP, Weiner M, Prabhakar M, Fiedorowicz JG. Mania and mortality: why the excess cardiovascular risk in bipolar disorder? Current psychiatry reports. 2009;11(6):475.
  22. Bostom AG, Gagnon DR, Cupples LA, Wilson P, Jenner JL, Ordovas JM, et al. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. Circulation. 1994;90(4):1688-95.

 

Journal of Kerman University of Medical Sciences
Volume 28, Issue 3
May and June 2021
Pages 230-235

Home

Editorial Board

Guide for Authors

Submit Manuscript

Guide for Reviewers

Contact Us